• Wednesday,September 25,2024
gecos.fr
X

Endeavor completes patient enrolment in trial of ENV-101

$ 18.50

4.5 (323) In stock

Share

Endeavor has concluded patient enrolment in a Phase IIa clinical trial of ENV-101 (taladegib) to treat idiopathic pulmonary fibrosis (IPF).

Endeavor completes patient enrolment in trial of ENV-101

Endeavor completes patient enrolment in trial of ENV-101